In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
1999
70.2K+
LTM Revenue $39.2B
LTM EBITDA $14.0B
$89.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GSK has a last 12-month revenue of $39.2B and a last 12-month EBITDA of $14.0B.
In the most recent fiscal year, GSK achieved revenue of $37.8B and an EBITDA of $11.3B.
GSK expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See GSK valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $42.5B | $36.5B | $37.8B | $39.2B | XXX |
Gross Profit | $28.0B | $24.6B | $27.1B | XXX | XXX |
Gross Margin | 66% | 67% | 72% | XXX | XXX |
EBITDA | $10.7B | $10.7B | $11.3B | $14.0B | XXX |
EBITDA Margin | 25% | 29% | 30% | 36% | XXX |
Net Profit | $5.5B | $18.6B | $6.1B | XXX | XXX |
Net Margin | 13% | 51% | 16% | XXX | XXX |
Net Debt | $23.8B | $20.5B | $17.5B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, GSK's stock price is GBP 14 (or $18).
GSK has current market cap of GBP 58.9B (or $73.4B), and EV of GBP 72.0B (or $89.7B).
See GSK trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$89.7B | $73.4B | XXX | XXX | XXX | XXX | $1.99 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, GSK has market cap of $73.4B and EV of $89.7B.
GSK's trades at 2.3x LTM EV/Revenue multiple, and 6.4x LTM EBITDA.
Analysts estimate GSK's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for GSK and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $89.7B | XXX | XXX | XXX |
EV/Revenue | 2.4x | XXX | XXX | XXX |
EV/EBITDA | 7.9x | XXX | XXX | XXX |
P/E | 12.0x | XXX | XXX | XXX |
P/E/Growth | 0.5x | XXX | XXX | XXX |
EV/FCF | 16.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGSK's NTM/LTM revenue growth is 4%
GSK's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, GSK's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate GSK's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for GSK and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 3% | XXX | XXX | XXX | XXX |
EBITDA Margin | 30% | XXX | XXX | XXX | XXX |
EBITDA Growth | 6% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 34% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 31% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
Opex to Revenue | 48% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GSK acquired XXX companies to date.
Last acquisition by GSK was XXXXXXXX, XXXXX XXXXX XXXXXX . GSK acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was GSK founded? | GSK was founded in 1999. |
Where is GSK headquartered? | GSK is headquartered in United Kingdom of Great Britain and Northern Ireland. |
How many employees does GSK have? | As of today, GSK has 70.2K+ employees. |
Who is the CEO of GSK? | GSK's CEO is Ms. Emma N. Walmsley. |
Is GSK publicy listed? | Yes, GSK is a public company listed on LON. |
What is the stock symbol of GSK? | GSK trades under GSK ticker. |
When did GSK go public? | GSK went public in 1972. |
Who are competitors of GSK? | Similar companies to GSK include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
What is the current market cap of GSK? | GSK's current market cap is $73.4B |
What is the current revenue of GSK? | GSK's last 12-month revenue is $39.2B. |
What is the current EBITDA of GSK? | GSK's last 12-month EBITDA is $14.0B. |
What is the current EV/Revenue multiple of GSK? | Current revenue multiple of GSK is 2.3x. |
What is the current EV/EBITDA multiple of GSK? | Current EBITDA multiple of GSK is 6.4x. |
What is the current revenue growth of GSK? | GSK revenue growth between 2023 and 2024 was 3%. |
Is GSK profitable? | Yes, GSK is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.